The Mayo Clinic estimates that menopause symptoms lead to $1.8 billion in lost work time per year in the U.S. About 5% of ...
The first life science tenant at Harvard’s new Allston development is a research center that could eventually become home to ...
6d
GlobalData on MSNGenentech wins FDA approval for second stroke treatmentGenentech’s label expansion for TNKase consolidates its market position for pharmacological stroke treatments.
The new center will be a hub for both Roche and Genentech, bringing together expertise in Cardiovascular, Renal, and ...
Advanced oncology pipeline including more than 20 active Phase 2 and Phase 3 clinical trials with a strategic focus on two priority pan-tumor ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug ...
F. Hoffmann-La Roche, one of the world’s largest biotechnology companies, announced on Thursday that it will establish an ...
Roche’s Genentech unit has received approval from the US Food and Drug Administration (FDA) for TNKase (tenecteplase) in ...
Roche and its Genentech subsidiary are planning to hitch up their cardiovascular, renal and metabolism R&D work and shift it over to a new center in Harvard’s Enterprise Research Campus. | Roche and ...
The hub has also been created to strengthen an existing relationship between Harvard and Roche that has been in place for over a decade.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results